Drug Patent List
Oppositions
Newsletter
Weekly Digest

Pharsight

Tedizolid Phosphate Patent Expiration

Tedizolid Phosphate is Used for treating acute bacterial skin and skin structure infections caused by susceptible bacteria. It was first introduced by Cubist Pharmaceuticals Llc in its drug Sivextro on Jun 20, 2014.


Tedizolid Phosphate Patents

Given below is the list of patents protecting Tedizolid Phosphate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Sivextro US10065947 Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate Feb 03, 2030 Cubist Pharms Llc
Sivextro US10442829 Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate Feb 03, 2030 Cubist Pharms Llc
Sivextro US7816379 Oxazolidinone derivatives Jun 20, 2028 Cubist Pharms Llc
Sivextro US8420676 Oxazolidinone derivatives Feb 23, 2028 Cubist Pharms Llc
Sivextro US8426389 Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate Dec 31, 2030 Cubist Pharms Llc
Sivextro US9624250 Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate Feb 03, 2030 Cubist Pharms Llc
Sivextro US9988406 Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate Feb 03, 2030 Cubist Pharms Llc


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Tedizolid Phosphate's patents.

Given below is the list recent legal activities going on the following patents of Tedizolid Phosphate.

Event Date Patent/Publication
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 09 Mar, 2023 US10442829
Payment of Maintenance Fee, 12th Year, Large Entity 09 Mar, 2022 US7816379
Payment of Maintenance Fee, 4th Year, Large Entity 09 Feb, 2022 US10065947
Payment of Maintenance Fee, 4th Year, Large Entity 11 Nov, 2021 US9988406
Payment of Maintenance Fee, 8th Year, Large Entity 15 Sep, 2020 US8426389
Payment of Maintenance Fee, 4th Year, Large Entity 15 Sep, 2020 US9624250
Payment of Maintenance Fee, 8th Year, Large Entity 15 Sep, 2020 US8420676
Patent Term Extension Certificate 29 Jul, 2020 US7816379
Notice of Final Determination -Eligible 13 Apr, 2020 US7816379
Notice of Final Determination -Eligible 19 Feb, 2020 US7816379



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳